D&D Pharmatech Inc. (KOSDAQ: 347850)

South Korea flag South Korea · Delayed Price · Currency is KRW
55,000
-1,700 (-3.00%)
Jan 21, 2025, 3:00 PM KST
66.67%
Market Cap 581.24B
Revenue (ttm) 8.19B
Net Income (ttm) -18.72B
Shares Out 10.57M
EPS (ttm) -1,905.21
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 153,493
Average Volume 406,910
Open 56,400
Previous Close 56,700
Day's Range 54,600 - 57,100
52-Week Range 25,100 - 64,000
Beta n/a
RSI 56.06
Earnings Date Mar 28, 2025

About D&D Pharmatech

D&D Pharmatech Inc., a clinical-stage biotech company, develops medicines in South Korea and the United States. It develops NLY01-PD, NLY01-AD, and NLY01-D that are in Phase II clinical trials for the treatment of Parkinson’s disease (PD), Alzheimer’s disease (AD), and type 2 diabetes; and P4M01, which has completed Phase IIa clinical trials to treat periodontal disease. The company also develops DD01 that is in Phase I clinical trials for the treatment of obesity/diabetes/nonalcoholic steatohepatitis (NASH); TLY012, which is Phase I clinical t... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2014
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 347850
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.